Native T1 mapping in diffuse myocardial diseases using 3-Tesla MRI: An institutional experience

Vimal Chacko Mondy; S Babu Peter; R Ravi

doi:10.4103/ijri.IJRI_326_20

Indian Journal of Radiology and Imaging, Table of Contents

CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2020; 30(04): 465-472
DOI: 10.4103/ijri.IJRI_326_20

Cardiac Imaging

Native T1 mapping in diffuse myocardial diseases using 3-Tesla MRI: An institutional experience

Vimal Chacko Mondy

Barnard Institute of Radiology, Madras Medical College, Chennai, Tamil Nadu, India

,

S Babu Peter

Barnard Institute of Radiology, Madras Medical College, Chennai, Tamil Nadu, India

,

R Ravi

Barnard Institute of Radiology, Madras Medical College, Chennai, Tamil Nadu, India

› Author Affiliations

Abstract

Aims: Newer cardiac magnetic resonance techniques like native T1 mapping are being used increasingly as an adjunct to diagnose myocardial diseases with fibrosis. However, its full clinical utility has not been tested extensively, especially in the Indian population. The purpose of this study was to find native T1 values in healthy individuals without cardiac disease in our 3-Tesla MRI system and examine whether native myocardial T1 values can be used to differentiate between normal and diffuse myocardial disease groups. Subjects and Methods: After approval from the institutional ethics committee, native T1 mapping was performed in 12 healthy individuals without cardiac disease who served as controls and in 26 patients with diffuse myocardial diseases (acute myocarditis (n = 5), hypertrophic cardiomyopathy (HCM) (n = 8), nonischemic dilated cardiomyopathy (DCM) (n = 7), restrictive cardiomyopathy (RCM) due to amyloidosis (n = 6)) in a 3-Tesla MRI system in short axis slices and four-chamber view using a modified Look-Locker inversion recovery sequence. The mean native T1 values and standard deviations were calculated for control and disease groups and compared. The ability of native myocardial T1 mapping to differentiate between normal and diffuse myocardial disease groups was assessed. One-way ANOVA with Tukey’s Post-Hoc test was used to find significant difference in the multivariate analysis and Chi-Square test was used to find the significance in categorical data. Results: The native T1 values for the healthy group in our 3-Tesla MRI system was 1186.47 ± 45.67 ms. The mean T1 values of the groups acute myocarditis (1418.68 ± 8.62 ms), HCM (1355.86 ± 44.67 ms), nonischemic DCM (1341.31 ± 41.48 ms), and RCM due to amyloidosis (1370.37 ± 90.14 ms) were significantly higher (P = 0.0005) than that of the healthy control group. Conclusion: Native myocardial T1 mapping is a promising tool for differentiating between healthy and diffuse myocardial disease groups.

Keywords

Cardiac magnetic resonance - cardiomyopathy - diffuse myocardial disease - modified look-locker inversion recovery - native T1 mapping

Full Text

References

References
1 Bishop JE, Greenbaum R, Gibson DG, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol 1990; 22: 1157-65
2 Brooks A, Schinde V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic myocardium. Heart 2003; 89: 1255-6
3 Schaper J, Speiser B. The extracellular matrix in the failing human heart. Basic Res Cardiol 1992; 87: 303-9
4 Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358: 1370-80
5 Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X, Fernández-Caggiano M. et al. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. Circulation 2012; 125: 789-802
6 Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM. et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010; 56: 875-87
7 Hinderer S, Schenke-Layland K. Cardiac fibrosis - A short review of causes and therapeutic strategies. Adv Drug Deliv Rev 2019; 146: 77-82
8 Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol 2017; 8: 1-8
9 From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc 2011; 86: 1095-102
10 Cunningham KS, Veinot JP, Butany J. An approach to endomyocardial biopsy interpretation. J Clin Pathol 2006; 59: 121-9
11 Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE. et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004; 25: 1940-65
12 Doltra A, Amundsen B, Gebker R, Fleck E, Kelle S. Emerging concepts for myocardial late gadolinium enhancement MRI. Curr Cardiol Rev 2013; 9: 185-90
13 Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K. et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008; 118: 1011-20
14 Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S. et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113: 2733-43
15 Kwon DH, Halley CM, Popovic ZB, Carrigan TP, Zysek V, Setser R. et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail 2009; 11: 937-44
16 Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M. et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977-85
17 Hinojar R, Foote L, Ucar EA, Jackson T, Jabbour A, Yu CY. et al. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: A proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging 2015; 8: 37-46
18 Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr 2009; 10: 15-21
19 Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-48
20 Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M. et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Hear Fail 2019; 12: 1-11
21 Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M. et al. Myocardial T1 mapping and extracellular volume quantification: A Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15: 1-22
22 Jellis CL, Kwon DH. Myocardial T1 mapping: Modalities and clinical applications. Cardiovasc Diagn Ther 2014; 4: 126-37
23 Kellman P, Hansen MS. T1-mapping in the heart: Accuracy and precision. J Cardiovasc Magn Reson 2014; 16: 2
24 Ferreira VM, Piechnik SK, Dallarmellina E, Karamitsos TD, Francis JM, Choudhury RP. et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: A comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14: 1-12
25 Dass S, Suttie JJ, Piechnik SK, Ferreira VM, Holloway CJ, Banerjee R. et al. Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 2012; 5: 726-33
26 Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK. et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014; 7: 157-65
27 Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G. et al. Identification and assessment of anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013; 6: 392-8
28 Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY. et al. T1 Mapping in discrimination of hypertrophic phenotypes: Hypertensive heart disease and hypertrophic cardiomyopathy: Findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2015; 8: e003285
29 Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Rai AB, Matthews PM. et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis-A clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson 2014; 16: 1-12
30 Puntmann VO, D’Cruz D, Smith Z, Pastor A, Choong P, Voigt T. et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging 2013; 6: 295-301
31 Xu J, Zhuang B, Sirajuddin A, Li S, Huang J, Yin G. et al. MRI T1 mapping in hypertrophic cardiomyopathy: Evaluation in patients without late gadolinium enhancement and hemodynamic obstruction. Radiology 2020; 294: 275-86
32 Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011; 57: 891-903
33 Gai N, Turkbey EB, Nazarian S, Van Der Geest RJ, Liu CY, Lima JAC. et al. T1 mapping of the gadolinium-enhanced myocardium: Adjustment for factors affecting interpatient comparison. Magn Reson Med 2011; 65: 1407-15
34 Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G. et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 2012; 98: 1436-41
35 Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium, part 1: Evaluation of an automated method. J Cardiovasc Magn Reson 2012; 14: 1-11
36 Teixeira T, Hafyane T, Stikov N, Akdeniz C, Greiser A, Friedrich MG. Comparison of different cardiovascular magnetic resonance sequences for native myocardial T1 mapping at 3T. J Cardiovasc Magn Reson 2016; 18: 1-12
37 Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified look-locker inversion recovery (MOLLI) for high-resolution T 1 mapping of the heart. Magn Reson Med 2004; 52: 141-6
38 Piechnik SK, Ferreira VM, Dall’Armellina E, Cochlin LE, Greiser A, Neubauer S. et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010; 12: 69
39 Kellman P, Herzka DA, Hansen MS. Adiabatic inversion pulses for myocardial T1 mapping. Magn Reson Med 2014; 71: 1428-34
40 Aherne E, Chow K, Carr J. Cardiac T1 mapping: Techniques and applications. J Magn Reson Imaging 2020; 51: 1336-56
41 Roujol S, Weingärtner S, Foppa M, Chow K, Kawaji K, Ngo LH. et al. Accuracy, precision, and reproducibility of four T1 mapping sequences: A headto-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology 2014; 272: 683-9
42 Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M. et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis the MyoRacer-Trial. J Am Coll Cardiol 2016; 67: 1800-11
43 Toussaint M, Gilles RJ, Azzabou N, Marty B, Vignaud A, Greiser A. et al. Characterization of benign myocarditis using quantitative delayed-enhancement imaging based on MOLLI T1 mapping. Med (United States) 2015; 94: 1-5
44 Roy C, Slimani A, De Meester C, Amzulescu M, Pasquet A, Vancraeynest D. et al. Age and sex corrected normal reference values of T1, T2 T2 * and ECV in healthy subjects at 3T CMR. J Cardiovasc Magn Reson 2017; 19: 1-12
45 Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K. et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 2013; 6: 475-84
46 Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A. et al. Reference values for healthy human myocardium using a T1 mapping methodology: Results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2014; 16: 69
47 Luetkens JA, Doerner J, Thomas DK, Dabir D, Gieseke J, Sprinkart AM. et al. Acute myocarditis: Multiparametric cardiac MR imaging. Radiology 2014; 273: 383-92
48 van den Boomen M, Slart RHJA, Hulleman EV, Dierckx RAJO, Velthuis BK, Van Der Harst P. et al. Native T1 reference values for nonischemic cardiomyopathies and populations with increased cardiovascular risk: A systematic review and meta-analysis. J Magn Reson Imaging 2018; 47: 891-912